中国实用儿科杂志 ›› 2024, Vol. 39 ›› Issue (11): 810-815.DOI: 10.19538/j.ek2024110602

• 专题笔谈 • 上一篇    下一篇

黏多糖贮积症Ⅰ型的诊治进展

  

  1. 浙江大学医学院附属儿童医院内分泌科,浙江  杭州  310052
  • 出版日期:2024-11-06 发布日期:2024-12-24
  • 通讯作者: 傅君芬,电子信箱:fjf68@zju.edu.cn

Diagnosis and treatment trends in mucopolysaccharidosis I

  1. Department of Endocrinology,Children’s Hospital Zhejiang University School of Medicine,Hangzhou  310052,China
  • Online:2024-11-06 Published:2024-12-24

摘要: 黏多糖贮积症Ⅰ型是一种由于溶酶体α-L-艾杜糖苷酶缺乏或活性降低,导致硫酸乙酰肝素和硫酸皮肤素在体内蓄积,而造成多器官进行性损害的致死性罕见常染色体隐性遗传病。黏多糖贮积症Ⅰ型的诊断需要结合临床表现、黏多糖测定、酶活性检测及基因检测进行。新生儿筛查对于黏多糖贮积症Ⅰ型的早期识别至关重要。目前的治疗方案主要是异基因造血干细胞移植、酶替代治疗及对症治疗,基因治疗仍处于研究阶段。

关键词: 黏多糖贮积症Ⅰ型, 诊断, 治疗

Abstract: Mucopolysaccharidosis type I is a rare and life-threating autosomal recessive disease caused by the deficiency of α-L-iduronidase,resulting in the accumulation of heparan sulfate and dermatan sulfate in the body,leading to progressive multiple organs dysfunction. The diagnosis of MPS type I is based on the quantification of α-l-iduronidase coupled with clinical manifestations,glycosaminoglycan analysis and gene sequencing. Newborn screening is now allowing the early identification of MPS I patients. The current treatment options are mainly allogeneic hematopoietic stem cell transplantation,enzyme replacement therapy and symptomatic treatment. Gene therapy is under development.

Key words: mucopolysaccharidosis type I, diagnosis, treatment